Sr Medical Director @Abbvie focused on drug development in Multiple Myeloma. Support pediatric brain tumor research and St. Jude. Tweets: my thoughts/opinions.
So proud of the work of UTHSC Malignant Hematology Team for hosting the Aplastic Anemia & MDS International Foundation (AAMDSIF) Patient and Family Conference this weekend! Organizer Dr. Swapna Thota https://t.co/oHKtwGEGq1
Read if you have few minutes.
Please support pediatric brain tumor research.
I cried while reading which is our normal now but there are many kids and parents who go through this. No child or parent should have to face this. Ever.
#PediatricBrainTumor#TeamAashvi#StJude
Join us at 7PM ETโฑ๏ธfor a live๐๐ขCME webinar, "Navigating the Changing Landscape in AML: Key Considerations in Treatment Delivery," featuring @chetasiTalatiMD, Dr. Erba and Dr. Pollyea๐ฉบ
Join Here: https://t.co/Te7UatW9nK
Working on a presentation highlighting the importance of clinical trials in hematological malignancies focusing on the enrollment of minorities and women. Minorities and women remain underrepresented, especially in early phase studies. We need to do better! #AMLSM#MDSSM
@jaltmanmd@MoffittNews@NFL @KendraSweetMD I made @KendraSweetMD join Twitter about a year ago and now forcefully tagging her when I can lol. Trying to get her to be a bit more active here. And we did have a blast at the game!
Never in my life I would have thought I would be at the Super Bowl! Thank you @MoffittNews and @NFL for an amazing and unreal experience! Go Tampa Bay Buccaneers!!! #SBLV with @KendraSweetMD and Asmita Mishra!
You might think not being able to develop an #HIV vaccine for 38 years was a big bust.
But all that work proved to be a warmup for success vs #SARSCoV2
https://t.co/x3ya8Nkidy by @GZuckerman@betswrites
For acute myeloid leukemia patients that cannot proceed to allogeneic stem cell transplant after induction, CC-486 is an alternative with survival advantage over placebo. More options for our patients fighting AML. #AMLSM
Older patients with acute myeloid leukemia were treated with intensive chemotherapy and randomly assigned to placebo or CC-486, the oral form of azactidine, daily for 14 days per 28-day cycle. CC-486 was associated with significantly longer relapse-free and overall survival.
@KuykendallMd@MoffittNews @KendraSweetMD @MJenningsPA Haha! I guess one of the two most exciting things! :). Birthing the baby was terrifying and exciting. Getting vaccinated was purely exiting!